Don’t Wait—Uncover the Clinical Endpoints that Will Matter to Payers and HCPs
PM360
APRIL 7, 2023
This option grows more critical as new therapies become available with price tags as high as $3.5 Analysis of Time-to-Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in Clinical Trials of Patients with Non-Small-Cell Lung Cancer.” million for the new hemophilia gene therapy. Blumenthal, G.M.
52 
Let's personalize your content